Physician profile
Warren E Austin
NPI 1700851953
$5,641.99
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $1,038 · 2021: $1,589 · 2022: $1,702 · 2023: $347 · 2024: $24.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $716.94 | 2019-2023 | Farxiga |
| Abbvie INC. | $627.28 | 2021-2023 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $546.25 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $377.38 | 2019-2023 | Emgality, Reyvow, Mounjaro |
| Pfizer INC. | $355.54 | 2019-2023 | |
| Amarin Pharma, INC. | $320.63 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $316.20 | 2022 | |
| Merck Sharp & Dohme LLC | $294.81 | 2019-2023 | Belsomra, Dificid |
| Allergan, INC. | $222.62 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $189.50 | 2021 | |
| Glaxosmithkline, LLC. | $133.38 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $131.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.42 | 2019-2021 | |
| Astellas Pharma US INC | $109.82 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.